EUA

Veru Inc. Sued By Block & Leviton LLP for Securities Law Violations

Retrieved on: 
Tuesday, January 10, 2023
COVID-19, EUA, District court, Certification, FDA, United States district court, Tiberius Claudius Verus, NDA, Food, Complaint, Pharmaceutical industry

BOSTON, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Block & Leviton LLP ( www.blockleviton.com ), a national securities litigation firm, announces that it has filed a class action lawsuit on behalf of shareholders against Veru Inc. (NASDAQ: VERU) and certain of its executives, for securities fraud.

Key Points: 
  • BOSTON, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Block & Leviton LLP ( www.blockleviton.com ), a national securities litigation firm, announces that it has filed a class action lawsuit on behalf of shareholders against Veru Inc. (NASDAQ: VERU) and certain of its executives, for securities fraud.
  • The complaint was brought in United States District Court for the Southern District of Florida and is captioned Ewing v. Veru Inc., et al., No.
  • A class has not yet been certified, and until certification occurs, you are not represented by an attorney.
  • Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country’s financial markets.

VERU INC. (NASDAQ: VERU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Veru Inc. (NASDAQ: VERU)

Retrieved on: 
Tuesday, January 10, 2023
Infection, News, Prostate cancer, Health minister, Aerospace, COVID-19, Prostate Cancer Foundation, EUA, District court, Trial of the century, Death, Safety, Breast, FDA, Fast track (FDA), NDA, Fast Track, Labour government, Patient, Steiner, Court, Mortality, Advertising, Investment, The Legal 500, Tobacco, Security (finance), Pharmaceutical industry, Verus Pharmaceuticals

NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU) between May 11, 2022 and November 9, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of Florida and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of Florida and alleges violations of the Securities Exchange Act of 1934.
  • Veru is primarily an oncology-based biopharmaceutical company that develops drugs for the management of breast and prostate cancers.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

ROSEN, A LEADING LAW FIRM, Encourages Veru, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– VERU

Retrieved on: 
Monday, January 9, 2023
Titan, EUA, FDA, Advertising, Class, Court, I-Space (Chinese company), Tobacco, Insurance, Marcus Annius Verus (grandfather of Marcus Aurelius)

WHAT TO DO NEXT: To join the Veru class action, go to https://rosenlegal.com/submit-form/?case_id=9728 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Veru class action, go to https://rosenlegal.com/submit-form/?case_id=9728 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Veru Inc. (VERU) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Pending

Retrieved on: 
Monday, January 9, 2023
News, COVID, EUA, FDA, Person, Steve Berman (lawyer), Patient, SAN, COVID 19, Pharmaceutical industry, Verus Pharmaceuticals

SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now .
  • VERU’s filings therefore concealed the true risks faced by the Company in gaining approval for its EUA request.
  • Investors learned the truth on Nov. 9, 2022, when Veru announced that the FDA advisory committee (“AdCom”) voted against approving sabizabulin under the agency’s EUA pathway.
  • If you invested in Veru and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bird, Generac, Veru, and Gap and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, January 9, 2023
News, Collectable, Fast track (FDA), Defendant, Compte rendu, Health minister, EUA, Death, Maintenance, Steiner, Bankruptcy, Mortality, Emphasis, FDA, NYSE, Fast Track, Generac Holdings, P.C, GPS, Infection, Market share, Security (finance), Prostate cancer, Form 10-Q, Aerospace, COVID-19, Gap, Standard of care, Trial of the century, Safety, Breast, Bird, NDA, Complaint, Audit committee, Annual report, Patient, Old Navy, Principle, Electricity, The Gap, Holding company, Renewable energy, Audit, Animal, Pharmaceutical industry, Verus Pharmaceuticals

For more information on the Bird class action go to: https://bespc.com/cases/BRDS

Key Points: 
  • For more information on the Bird class action go to: https://bespc.com/cases/BRDS
    Generac is a Wisconsin-based producer of residential generators and backup power systems.
  • Throughout the Class Period, numerous consumers filed complaints with regulators, and Generac's channel partners informed the Company of the SnapRS defect.
  • For more information on the Veru class action go to: https://bespc.com/cases/VERU
    According to the Complaint, the Company made false and misleading statements to the market.
  • Gap suffered from significant management errors in its Old Navy brand, specifically related to the "BODEQUALITY" program which impacted its financial results.

DEADLINE ALERT for EIGR, TSP, and UIS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Monday, January 9, 2023
Eiger, COVID-19, EUA, Law, FDA, Defendant, Suite, Complaint, Peginterferon-alfa, Investment, Mail, Holding company, Risk management, Unisys, Hydron

LOS ANGELES, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

Nasal Vaccines Global Markets and Pipeline Analysis Research Report 2022 - Trends and Sales Forecasts through 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Health, Infectious Diseases, Hospital, COVID, Sputnik 1, Syringe, Immunity, PESTEL, Needle, COVID-19, International finance, Virus, EUA, Drug, Severe acute respiratory syndrome coronavirus 2, Pressure, Government, FDA, Vaccination, Influenza and Other Respiratory Viruses, Vaccine, AstraZeneca, Growth, Intelligence, Coronavirus, Research, Pharmacy, Bharat Biotech, Nose, USD, Gamaleya, Two-phase electric power, Pharmaceutical industry

The "Nasal Vaccines: Global Markets and Pipeline Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nasal Vaccines: Global Markets and Pipeline Analysis" report has been added to ResearchAndMarkets.com's offering.
  • This report examines trends and sales in the global market for nasal vaccines through 2027.
  • Nasal vaccines achieve both: They eliminate the use of needles, thus reducing the cost of vaccines and facilitating mass vaccination.
  • The report examines all forms of nasal vaccines, such as nasal drops or sprays, but excludes intramuscular and oral vaccines.

Deadline Alert: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Notifies Eiger BioPharmaceuticals, Inc. (EIGR) Investors of Class Action and Encourages Investors to Actively Participate

Retrieved on: 
Monday, January 9, 2023
Legal, Professional Services, COVID-19, Peginterferon-alfa, Person, EUA, EAU, Court, FDA, Complaint, Eiger

Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/eigr .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/eigr .
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements, and failed to disclose material adverse facts about the Company’s business, operational, and compliance policies.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.

BD, CerTest Biotec Announce Emergency Use Authorization for Mpox Diagnostic Test

Retrieved on: 
Monday, January 9, 2023
TNA, Food, Emergency Use Authorization, Urinary tract infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Molecular diagnostics, Research, World Health Organization's response to the COVID-19 pandemic, Becton, Disease, NYSE, Infection, EUA, Becton, Dickinson and Company headquarters, Health, FDA, BD, BDX, Vaccine, Diagnosis, PCR, Pharmaceutical industry, Computer data storage

FRANKLIN LAKES, N.J., Jan. 9, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and CerTest Biotec have announced Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a molecular polymerase chain reaction (PCR) assay for Mpox virus detection.

Key Points: 
  • The VIASURE Monkeypox Virus Real Time PCR Reagents for BD MAX System* is now available for BD MAX™ System users.
  • "The Mpox outbreak continues to be designated as a global health emergency — the World Health Organization's highest level of alert," said Nikos Pavlidis, vice president of Molecular Diagnostics at BD.
  • "We were able to quickly develop the VIASURE mpox molecular test by leveraging the BD MAX™ System's open system reagent suite," said Nelson Fernandes, managing director of CerTest Biotec.
  • As with all CerTest assays, the VIASURE Monkeypox Virus PCR Detection assay for the BD MAX™ System is offered in a lyophilized format.

Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference

Retrieved on: 
Sunday, January 8, 2023
Emergency Use Authorization, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Party, Infection, COVID-19, Partner, Novartis, EUA, Letter, DLL3, Molecular Partners, Definitive, Intellectual property, FDA, Therapy, Conference, DARPin, Pharmaceutical industry, CONCORD

Expression of DLL3 is low in healthy tissue but significantly increased in certain tumor types, providing an opportunity for selective targeting.

Key Points: 
  • Expression of DLL3 is low in healthy tissue but significantly increased in certain tumor types, providing an opportunity for selective targeting.
  • *
    Molecular Partners and Novartis signed a non-binding letter of intent to negotiate a Research Framework Agreement with a primary focus on emerging infectious global health threats.
  • Patrick Amstutz, CEO of Molecular Partners, will present at the 41st Annual JP Morgan Healthcare Conference on Wednesday, January 11 at 10:30 AM ET (4:30 PM CET).
  • A webcast will be accessible on the Molecular Partners website, under the Events tab .